CLINICAL TRIALS PROFILE FOR BREMELANOTIDE ACETATE
✉ Email this page to a colleague
All Clinical Trials for bremelanotide acetate
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT05709444 ↗ | A Phase IIb, Multicenter, Open-Label, Prospective Study of Bremelanotide in Diabetic Kidney Disease | Recruiting | Palatin Technologies, Inc | Phase 2 | 2022-12-29 | This is a prospective, open-label trial to assess the efficacy of melanocortin receptor agonist bremelanotide (BMT) when administered with RAAS inhibition therapy after six months in subjects with Type II diabetic nephropathy. After six months of therapy, all subjects will remain in trial for further assessment and undergo a diagnostic renal biopsy to assess the effect of melanocortin therapy on diabetic histopathology at 12 months. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for bremelanotide acetate
Condition Name
Clinical Trial Locations for bremelanotide acetate
Trials by Country
Clinical Trial Progress for bremelanotide acetate
Clinical Trial Phase
Clinical Trial Sponsors for bremelanotide acetate
Sponsor Name